



# Cartilage tissues regulate systemic aging *via* ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice

Received for publication, July 21, 2023, and in revised form, November 9, 2023. Published, Papers in Press, November 30, 2023.  
<https://doi.org/10.1016/j.jbc.2023.105512>

Takahiro Arima<sup>1,‡</sup>, Kazuki Sugimoto<sup>1,‡</sup>, Takuya Taniwaki<sup>1</sup>, Kazuya Maeda<sup>1</sup>, Yuto Shibata<sup>1</sup>, Makoto Tateyama<sup>1</sup>, Tatsuki Karasugi<sup>1</sup>, Takuya Tokunaga<sup>1</sup>, Takanao Sueyoshi<sup>1</sup>, Satoshi Hisanaga<sup>1</sup>, Tetsuro Masuda<sup>1</sup>, Yusuke Uehara<sup>1</sup>, Masaki Yugami<sup>1</sup>, Kozo Matsushita<sup>1</sup>, Ryuji Yonemitsu<sup>1</sup>, Junki Kawakami<sup>1</sup>, Naoto Yoshimura<sup>1</sup>, Shuntaro Tanimura<sup>1</sup>, Hajime Kato<sup>2</sup>, Nobuaki Ito<sup>2</sup>, Kenichi Inoue<sup>3</sup>, Kana Bando<sup>3</sup>, Takayuki Nakamura<sup>1,\*</sup>, and Takeshi Miyamoto<sup>1,\*</sup>

From the <sup>1</sup>Department of Orthopedic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; <sup>2</sup>Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan; <sup>3</sup>Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe, Hyogo, Japan

Reviewed by members of the JBC Editorial Board. Edited by Philip A. Cole

Aging presents fundamental health concerns worldwide; however, mechanisms underlying how aging is regulated are not fully understood. Here, we show that cartilage regulates aging by controlling phosphate metabolism *via* ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1). We newly established an Enpp1 reporter mouse, in which an EGFP-luciferase sequence was knocked-in at the *Enpp1* gene start codon (Enpp1/EGFP-luciferase), enabling detection of Enpp1 expression in cartilage tissues of resultant mice. We then established a cartilage-specific Enpp1 conditional knockout mouse (Enpp1 cKO) by generating Enpp1 flox mice and crossing them with cartilage-specific type 2 collagen Cre mice. Relative to WT controls, Enpp1 cKO mice exhibited phenotypes resembling human aging, such as short life span, ectopic calcifications, and osteoporosis, as well as significantly lower serum pyrophosphate levels. We also observed significant weight loss and worsening of osteoporosis in Enpp1 cKO mice under phosphate overload conditions, similar to global Enpp1-deficient mice. Aging phenotypes seen in Enpp1 cKO mice under phosphate overload conditions were rescued by a low vitamin D diet, even under high phosphate conditions. These findings suggest overall that cartilage tissue plays an important role in regulating systemic aging *via* Enpp1.

Aging is a complex physiological process experienced universally, although its rate of progression varies; how that rate is controlled, however, has not been characterized. Phosphate homeostasis is tightly regulated, and controlling phosphate metabolism is believed crucial to the aging process (1–3). Loss of either *Klotho* or *FGF23* disrupts phosphate metabolism and in mouse promotes phenotypes mimicking human aging, including short life span and arteriosclerosis (4–6). Furthermore, loss-of-function mutations in either *KLOTHO* or *FGF23* reportedly underlie tumoral calcinosis, a disease characterized in humans by ectopic vascular calcifications (7, 8). Thus, the *FGF23*-*Klotho* axis

is required and conserved to regulate phosphate metabolism and control the rate of aging in humans and mice.

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1), a transmembrane protein, generates pyrophosphate (PPi), which inhibits hydroxyapatite crystal deposition and mineralization in tissues (9, 10). *ENPP1* mutations have been detected in patients with autosomal recessive hypophosphatemic rickets type 2 or generalized arterial calcification of infancy (10–13). *ENPP1* mutation is also seen in patients with ossification of the posterior longitudinal ligament, a disease characterized by ectopic ossification in spinal ligaments (14, 15), suggesting that *ENPP1* plays essential roles in regulating phosphate metabolism and antagonizing ectopic calcification in humans. Furthermore, loss-of-function mutations in *Enpp1*, namely those seen in *Enpp1*<sup>ttw/ttw</sup> (G1813 T) (16, 17) or *Enpp1*<sup>asj/asj</sup> (V246D) mice (18), have been reported. *Enpp1*<sup>ttw/ttw</sup> mice exhibit ossification of the posterior longitudinal ligament-like ectopic spinal ligament ossification (16, 17), whereas, *Enpp1*<sup>asj/asj</sup> mice reportedly exhibit generalized arterial calcification of infancy-like phenotypes (18). *Enpp1*<sup>ttw/ttw</sup> mice also exhibit premature aging phenotypes under phosphate overload conditions (6, 19, 20), similar to *Klotho*-mutant mice. Enpp1 is expressed in bone, cartilage, fat, heart, and liver tissues (21–24), but it remains unclear which tissue is predominant in regulating aging phenotypes through Enpp1.

Here, we established mice with EGFP-luciferase knock-in at the Enpp1 gene and observed specific Enpp1 expression in cartilage tissues. We then established Enpp1 flox mice and used them to successfully generate cartilage-specific Enpp1 conditional knockout mice (Col2 Cre/Enpp1 cKO). Those mice exhibited various aging-related phenotypes including osteoporosis and ectopic calcium deposition in tissues, such as kidney and spinal ligament under phosphate overload conditions. Thus, we conclude that Enpp1 activity in cartilage is required to regulate global phosphate metabolism, ectopic ossification, and aging.

## Results

### *Enpp1* is robustly expressed in chondrocytes

To identify tissues expressing Enpp1 *in vivo*, we generated knock-in (KI) mice with a chimeric EGFP/firefly luciferase

<sup>‡</sup> These authors contributed equally to this work.

\* For correspondence: Takayuki Nakamura, [takayuki-n@kuh.kumamoto-u.ac.jp](mailto:takayuki-n@kuh.kumamoto-u.ac.jp); Takeshi Miyamoto, [miyamoto.takeshi@kuh.kumamoto-u.ac.jp](mailto:miyamoto.takeshi@kuh.kumamoto-u.ac.jp).


## Cartilage tissues regulate systemic aging via *Enpp1* in mice

signal incorporated into *Enpp1* exon1 (Fig. 1A). We then administered D-luciferin (0.15 mg/g) intraperitoneally to 4-week-old KI and wildtype (WT) mice and performed *in vivo* imaging analysis 15 to 30 min later. As expected, we detected no luminescence in WT mice, while KI mice displayed luminescence (Fig. 1B). For further analysis, we then dissected various organs from KI mice and observed strong luminescence in ribs, lower limbs, and spine, all of which contain cartilage regions, but almost no luminescence signals in kidney, liver, or spleen (Fig. 1C). To assess *Enpp1* expression sites in greater detail, we performed immunofluorescence staining of EGFP on frozen sections of femoral heads from WT and KI mice. While no EGFP staining was evident in WT mice, articular cartilage and growth plate chondrocytes in KI mice were EGFP positive (Fig. 1D). We also isolated and cultured chondrocytes from rib cartilage of 1-week-old WT and KI mice and subjected them to immunofluorescent staining, followed by luminescence analysis 15 min after adding D-luciferin. Chondrocytes from KI mice were doubly positive for anti-type 2 collagen, a marker of chondrocytes, and anti-EGFP antibodies, whereas chondrocytes from WT mice were only positive for the anti-type 2 collagen antibody (Fig. 1E).


Furthermore, KI cells exhibited luminescence, which was absent in WT cells (Fig. 1F), indicating specific expression of *Enpp1* in chondrocytes.

### Global *Enpp1*-conditional knockout mice exhibit aging phenotypes

The above findings suggest that *Enpp1* may regulate bone and phosphorus metabolism from chondrocytes. Thus, we generated *Enpp1* flox/flox mice in which loxP sequences were incorporated at both ends of *Enpp1* exon18 (Fig. 2A), since exon18 is mutated in *ttw* mice (17). We then crossed *Enpp1* flox/flox mice with CAG Cre Tg mice to obtain CAG Cre, *Enpp1* flox/flox mice (hereafter referred to as CAG Cre/*Enpp1* cKO mice), which are globally *Enpp1* deficient. CAG Cre/*Enpp1* cKO mice exhibited tip-toe walking at 3 to 4 weeks of age (Fig. S1) and showed significantly reduced body weight compared to control mice (Cre-, *Enpp1* flox/flox mice) (Fig. 2, B and C), both phenotypes seen in *ttw* mice. We then isolated total RNA from femoral head cartilage, bone, and small intestine tissues in CAG Cre/*Enpp1* cKO mice and performed real-time PCR, which showed that *Enpp1* expression levels



**Figure 1. *Enpp1* is specifically expressed in chondrocytes.** A, we generated reporter mice by knocking in a chimeric sequence, EGFP-firefly luciferase, at the start codon of exon 1 of mouse *Enpp1* (KI mouse). B and C, D-luciferin (0.15 mg/g body weight) was administered intraperitoneally to 4-week-old KI and wildtype (WT) mice, and 15 to 30 min later, *in vivo* imaging was performed (B). Bar, 20 mm. Luminescence signals were also monitored *ex vivo* in individual organs removed from KI mice (C). Bar, 20 mm. D, undecalcified frozen sections of femoral head were prepared in 4-week-old WT and KI mice, stained with HE or rabbit anti-EGFP antibody (diluted 1:1000) followed by Alexa488-conjugated goat anti-rabbit Ig's antibody (diluted 1:400), and observed under a microscope (left panels) or a fluorescence microscope (right panels). Nuclei are stained with DAPI. Bar, 100  $\mu$ m. E, primary chondrocytes were isolated from rib cartilage of 1-week-old WT or KI mice and stained with goat anti-EGFP antibody (diluted 1:250) and rabbit anti-Type2 collagen (diluted 1:200) followed by Alexa488-conjugated Donkey anti-Goat Ig's (diluted 1:200) and Alexa594-conjugated Donkey anti-rabbit Ig's antibodies (diluted 1:200). Nuclei were stained with DAPI. Cells were observed under a fluorescence microscope. Bar, 50  $\mu$ m. F, pellet cultured cells shown in (E) were incubated 15 min with D-luciferin (0.5 mM), and chemiluminescence was analyzed. *Enpp1*, Ectonucleotide pyrophosphatase/phosphodiesterase 1; KI, knock-in.



**Figure 2. CAG Cre/Enpp1 cKO mice exhibit phenotypes similar to those seen in *ttw* mice.** *A*, generation of *Enpp1*-floxed mice. Mice with loxP sites flanking exon 18 were subsequently crossed with CAG Cre mice to yield CAG Cre; *Enpp1*<sup>fl/fl</sup>(CAG Cre/Enpp1 cKO) mice, in which *Enpp1* is globally deleted. *B*, changes in body weight in indicated cKO and control male and female mice over the period between 4 and 8 weeks of age. Data represent mean weight (g) of each time point  $\pm$  SD (cKO,  $n = 10$ , control,  $n = 12$ ,  $***p < 0.001$ ). *C*, gross appearance of 8-week-old CAG Cre/Enpp1 cKO and control mice. *D*, RNA was extracted from head articular cartilage from 8-week-old *Enpp1*<sup>fl/fl</sup>(control), *ttw*, or CAG Cre/Enpp1 cKO mice, and *Enpp1* expression analyzed by real-time PCR. *E*, plasma was collected from 8-week-old mice in groups shown in (*D*), and plasma PPI was assessed using ATP sulfurylase. In (*D* and *E*) data represent mean *Enpp1* expression relative to  $\beta$ -actin (*D*) or plasma PPI  $\pm$  SD (*E*), respectively (WT and *ttw*, CAG Cre/Enpp1 cKO;  $n = 6$ ,  $**p < 0.01$ , ns, not significant). *F*, micro CT images of cervical spine (upper) and ankle joints (lower) of 8-week-old CAG Cre/Enpp1 cKO or *Enpp1*<sup>fl/fl</sup>(control) mice. *G*, undecalcified frozen sections of cervical spine from 8-week-old CAG Cre/Enpp1 cKO and *Enpp1*<sup>fl/fl</sup>(control) mice stained with von Kossa. Arrowheads in (*F* and *G*) indicate ectopic calcification. Bar, 100  $\mu$ m. *H*, indicated groups of 8-week-old female were fed a normal (ND) or high-phosphate (HPD) diet, and changes in body weight (upper panel) and survival rate (lower panel) were monitored. Data represent mean body weight (g) at indicated time point  $\pm$  SD (CAG Cre/Enpp1 cKO fed a ND or HPD;  $n = 6$ , control fed a ND or HPD;  $n = 10$ ,  $***p < 0.001$ ). CAG Cre/Enpp1 cKO mice, CAG Cre, *Enpp1* <sup>fl/fl</sup> mice; *Enpp1*, Ectonucleotide pyrophosphatase/phosphodiesterase 1; KI, knock-in; PPI, pyrophosphate.

were significantly decreased compared to those in control mice (Figs. 2*D* and S2). Moreover, *Enpp1* expression levels in cartilage were comparable in CAG Cre/Enpp1 cKO and *ttw* mice (Fig. 2*D*). Since *Enpp1* functions in PPI generation (9), we measured plasma PPI levels and found they were significantly decreased in CAG Cre/Enpp1 cKO compared to control mice (Fig. 2*E*). Micro CT imaging of cervical spine and ankle joints of 8-week-old CAG Cre/Enpp1 cKO mice revealed ectopic calcification around the intervertebral discs and Achilles tendon (Fig. 2*F*), both reportedly seen in *ttw* mice (25). We then performed von Kossa staining using frozen sagittal sections of cervical vertebrae from CAG Cre/Enpp1 cKO mice and observed ectopic calcification around intervertebral discs (Fig. 2*G*).

In *ttw* mice, high-phosphate diet (HPD) is known to cause early aging and weight loss phenotypes (19, 20). To determine whether CAG Cre/Enpp1 cKO mice exhibit similar phenotypes, we fed 8-week-old CAG Cre/Enpp1 cKO and control mice either a normal diet (ND) or a HPD. The CAG Cre/Enpp1 cKO HPD group exhibited significant weight loss compared to the three other groups, and all CAG Cre/Enpp1 cKO HPD mice died within 4 to 5 weeks (Fig. 2*H*). Overall, we

conclude that *Enpp1* <sup>fl/fl</sup> mice can successfully be made conditionally deficient in *Enpp1* using the Cre-loxP system and that resulting CAG Cre/Enpp1 cKO mice exhibit phenotypes comparable to *ttw* mice.

### Cartilage-specific *Enpp1* conditional knockout mice exhibit aging phenotypes

Type2 collagen is reportedly expressed in tissues such as cartilage, the nucleus pulposus of intervertebral discs and the vitreous body, but is primarily expressed in chondrocytes (26, 27). To assess effects of *Enpp1* loss in chondrocytes, we crossed *Enpp1* <sup>fl/fl</sup> mice with Type 2 collagen Cre Tg mice to eliminate *Enpp1* specifically in chondrocytes (hereafter referred to as Col2 Cre/Enpp1 cKO mice). Indeed, we detected chondrocyte-specific EGFP expression in Col2 Cre/loxP-EGFP reporter mice (Fig. S3), which showed specific EGFP expression in type 2 collagen-expressing cells. After immunostaining for EGFP, sagittal frozen sections of cervical vertebrae from these mice exhibited specific EGFP staining in the nucleus pulposus in intervertebral discs and in growth plate chondrocytes in endplates (Fig. S3).

## Cartilage tissues regulate systemic aging via *Enpp1* in mice

We then performed real-time PCR from total RNA from femoral head cartilage of Col2 Cre/*Enpp1*cKO mice and observed significantly decreased *Enpp1* expression levels relative to control (*Enpp1* flox/flox) mice (Fig. 3A). No significant decrease in *Enpp1* expression relative to controls was seen in other tissues from Col2 Cre/*Enpp1*cKO mice (Fig. S4). Although Col2 Cre/*Enpp1* cKO and control mice showed comparable body weight (Fig. 3B) and Col2 Cre/*Enpp1* cKO mice did not exhibit tip-toe walking at 8 weeks of age, micro CT imaging of the cervical spine revealed ectopic calcification around the intervertebral disc at the 8-weeks' time point in Col2 Cre/*Enpp1* cKO mice (Fig. 3C). Von Kossa staining of cervical spine confirmed ectopic calcification in the same area detected by micro CT in Col2 Cre/*Enpp1* cKO mice (Fig. 3D). Plasma PPI levels were significantly reduced in 8-week-old Col2 Cre/*Enpp1*cKO relative to WT mice (Fig. 3E). These results indicate that Col2 Cre/*Enpp1* cKO mice recapitulate phenotypes seen in *ttw* and CAG Cre/*Enpp1* cKO mice, although phenotypes in Col2 Cre/*Enpp1* cKO mice are milder.


### Col2 Cre/*Enpp1* cKO mice exhibit systemic aging phenotypes

Since Col2 Cre/*Enpp1* cKO mice show phenotypes similar to those seen in *ttw* mice (specifically, phenotypes resembling

human aging (20)), we performed longitudinal studies of aging in Col2 Cre/*Enpp1* cKO mice (Fig. 4). Relative to control mice, *Enpp1* cKO mice had a significantly shorter life span (Fig. 4A). We also analyzed the percentage of p16-positive cells in intervertebral disc tissues in Col2 Cre/*Enpp1* cKO and control mice, since p16 is a known marker of cell senescence (28). At 8 weeks of age, the percentage of p16-positive cells was significantly higher in *Enpp1* cKO than in control mice. However, at 15 weeks of age, those percentages remained higher in *Enpp1* cKO compared to control mice, but differences were not significant (Fig. 4, B and C). The frequency of mesenchymal stem/progenitor cells, defined as CD45-negative/CD31-negative/PDGF receptor alpha-positive cells, in bone marrow was comparable between genotypes at 8 weeks of age (Fig. S5) and also comparable to the frequency seen in control mice at 15 weeks; however, that frequency was decreased in *Enpp1* cKO relative to control mice at 15 weeks, although the difference was not significant (Fig. S5).


### Phenotypes seen in Col2 Cre/*Enpp1* cKO mice are accelerated by high phosphate conditions

Next, we fed 8-week-old Col2 Cre/*Enpp1* cKO and control (*Enpp1* flox/flox mice) mice ND and HPD diets, since *ttw* mice



**Figure 3. Col2 Cre/*Enpp1* flox mice exhibit phenotypes similar to those seen in *ttw* mice.** Col2 Cre and *Enpp1*-flox mice were crossed to yield Col2 Cre; *Enpp1*flox/flox (Col2 Cre/*Enpp1* cKO) mice, in which *Enpp1* is specifically knocked out in chondrocytes. **A**, RNA was extracted from femoral head articular cartilage in indicated 8-week-old mice and *Enpp1* expression analyzed by real-time PCR. Data represent mean *Enpp1* expression relative to  $\beta$ -actin (**A**) ( $n = 7$ ,  $**p < 0.01$ , ns, not significant). **B–D**, Col2 Cre/*Enpp1* cKO or *Enpp1*flox/flox (control) male and female mice were fed a ND for 8 weeks. **B**, changes in body weight in indicated groups over a period when mice were 4 to 8 weeks of age. Data represent mean weight (g) of each time point  $\pm$  SD ( $n = 6$ , ns, not significant). **C**, micro CT imaging of cervical spine of indicated 8-week-old mice. **D**, undecalcified frozen sections of cervical spine from indicated 8-week-old mice stained with von Kossa. Arrowheads in (**C** and **D**) indicate calcification. Bar, 100  $\mu$ m. **E**, plasma was collected from 8-week-old wildtype, *ttw*, and Col2 Cre/*Enpp1* cKO mice, and plasma PPI was assessed using ATP sulfurylase. Data represent mean plasma PPI  $\pm$  SD ( $n = 6$ ,  $*p < 0.05$ , ns, not significant). Col2 Cre/*Enpp1*cKO mice, type 2 collagen Cre; *Enpp1* flox/flox mice; *Enpp1*, Ectonucleotide pyrophosphatase/phosphodiesterase 1; PPI, pyrophosphate.


## Cartilage tissues regulate systemic aging via *Enpp1* in mice



**Figure 4. Col2 Cre/Enpp1 cKO mice exhibit systemic aging phenotypes.** *A*, weeks of survival were quantified using the Kaplan–Meier log rank survival test (each group;  $n = 12$ ). *B*, undecalcified frozen sections of cervical spine were prepared from 8- to 15-week-old *Enpp1* flox/flox (control) or Col2 Cre/Enpp1 cKO mice, stained with rabbit anti-p16INK4a antibody followed by Alexa488-conjugated goat anti-rabbit Ig antibody, and observed by fluorescence microscopy. Nuclei were DAPI stained. *Arrowheads* in (*B*) indicate p16-positive cells. Bar, 25  $\mu$ m. *C*, the number of p16-positive cells relative to the total number of DAPI-stained nuclei in the intervertebral disc was scored. All values represent means  $\pm$ SD ( $n = 6$ ,  $*p < 0.05$ ). Col2 Cre/Enpp1 cKO mice, type 2 collagen Cre; *Enpp1* flox/flox mice; *Enpp1*, Ectonucleotide pyrophosphatase/phosphodiesterase 1.

fed a HPD show weight loss and accelerated ectopic calcification in tissues, such as spine and kidney (20). Col2 Cre/Enpp1 cKO mice fed a HPD showed significant weight loss compared to Col2 Cre/Enpp1 cKO mice fed a ND or controls fed a HPD for the same time period (Fig. 5, *A* and *B*). Micro CT imaging performed in 15-week-old mice after 7 weeks on

the ND or HPD revealed ectopic ossification around the intervertebral disc in Col2 Cre/Enpp1 cKO mice fed a ND, which was enhanced in Col2 Cre/Enpp1 cKO mice fed a HPD (Fig. 5*C*). Von Kossa staining of cervical spine confirmed worsened ectopic calcification, as detected by micro CT in Col2 Cre/Enpp1 cKO mice fed the HPD (Fig. 5*D*). We also



**Figure 5. A high-phosphate diet promotes weight loss in Col2 Cre/Enpp1 cKO mice.** Eight-week-old *Enpp1* flox/flox (control) and Col2 Cre/Enpp1 cKO mice were fed a normal diet (ND) or high-phosphate diet (HPD) for 7 weeks (*A–E*). *A*, changes in body weight in indicated groups over a period when mice were 8 to 15 weeks of age. Data represent mean weight (g) of each time point  $\pm$ SD ( $n = 7$ ,  $*p < 0.05$ ). *B*, gross appearance of 15-week-old mice in indicated groups. *C*, micro CT imaging of cervical spine of 15-week-old mice from indicated groups. *D*, undecalcified frozen sections of cervical spine were prepared in indicated 15-week-old mice and stained with von Kossa. In (*C* and *D*) *arrowheads* indicate ectopic calcification. Bar, 100  $\mu$ m. *E*, undecalcified frozen sections of kidney were prepared in indicated 15-week-old mice and stained with Alizarin Red. Regions boxed in *upper panels* are shown at high magnification in adjacent *lower panels*. Bar, 500  $\mu$ m. Col2 Cre/Enpp1 cKO mice, type 2 collagen Cre; *Enpp1* flox/flox mice; *Enpp1*, Ectonucleotide pyrophosphatase/phosphodiesterase 1.

## Cartilage tissues regulate systemic aging via *Enpp1* in mice

detected accelerated ectopic calcification in kidneys of 15-week-old Col2 Cre/*Enpp1* cKO mice fed the HPD (Fig. 5E). No obvious ectopic calcification in kidney was observed in either control group or in Col2 Cre/*Enpp1* cKO mice fed a ND (Fig. 5E). We conclude that phosphate supplementation accelerates aging phenotypes in Col2 Cre/*Enpp1* cKO mice, as seen in *ttw* mice. *ttw* mice fed a HPD showed reduced expression of the *Klotho* gene, which encodes a coreceptor of fibroblast growth factor receptor, but those mice exhibited relatively higher *Cyp27b1* transcript levels in kidney (20). Indeed, 15-week-old Col2 Cre/*Enpp1* cKO mice fed a HPD for 7 weeks exhibited significantly reduced *Klotho* transcript levels, as seen in kidney of 10-week-old *ttw* mice (Fig. S6). Moreover, *Cyp27b1* expression in kidney was comparable in 15-week-old control mice fed either a ND or a HPD for 7 weeks, whereas it was significantly upregulated in kidney of 15-week-old Col2 Cre/*Enpp1* cKO mice fed a HPD for 7 weeks, as seen in similarly treated *ttw* mice (Fig. S7).

### Phenotypes seen in Col2 Cre/*Enpp1* cKO mice are rescued by a low vitamin D diet


Phenotypes of *ttw* mice fed a HPD are reportedly rescued by a high phosphate/low vitamin D diet (HPLD) (20). Thus, we fed 8-week-old Col2 Cre/*Enpp1* cKO mice either a HPD or

HPLD. The significant body weight loss seen in Col2 Cre/*Enpp1* cKO mice fed a HPD was significantly rescued by feeding the HPLD (Fig. 6, A and B). At 15 weeks of age, when mice had been fed the HPD or HPLD for 7 weeks, micro CT imaging showed that ectopic ossification around the intervertebral disc seen in Col2 Cre/*Enpp1* cKO mice was enhanced by the HPD but not by the HPLD (Fig. 6C).

Von Kossa staining of cervical spine confirmed enhancement of ectopic calcification in spine by the HPD but not the HPLD in Col2 Cre/*Enpp1* cKO mice (Fig. 6D). Similarly, histological analysis using Alizarin red staining showed that ectopic calcification in kidney was accelerated by a HPD but not a HPLD in Col2 Cre/*Enpp1* cKO mice (Fig. 6E). Furthermore, bone mineral density was significantly decreased in Col2 Cre/*Enpp1* cKO mice fed a HPD relative to what other three groups, but this decrease was not seen in Col2 Cre/*Enpp1* cKO mice fed the HPLD (Fig. 6F). These results indicate that elevated vitamin D3 levels may underlie induction of aging phenotypes of Col2 Cre/*Enpp1* cKO mice fed an HPD.

### Discussion

Aging is a multifactorial process, and its rate is thought to be determined by a combination of individual and environmental factors (29–31). However, it has been unclear whether a



**Figure 6. A low vitamin D diet antagonizes aging phenotypes seen in Col2 cKO mice under phosphate overload.** Eight-week-old Col2 Cre/*Enpp1* cKO mice were fed a HPD or a high phosphate/low vitamin D diet (HPLD) for 7 weeks (A–F). A, changes of body weight in indicated groups over a period when mice were 8 to 15 weeks of age. Data represent mean weight (g) of each time point  $\pm$  SD ( $n = 8$ ,  $***p < 0.001$ ). B, gross appearance of 15-week-old indicated mice. C, micro CT imaging of cervical spine of indicated 15-week-old mice. D, undecalcified frozen sections of cervical spine from 15-week-old indicated mice stained with von Kossa. In (C and D) arrowheads indicate calcification. Bar, 100  $\mu$ m. E, undecalcified frozen sections of kidney from 15-week-old indicated mice stained with Alizarin Red. Regions boxed in upper panels are shown at high magnification in adjacent lower panels. Bar, 500  $\mu$ m. F, bone mineral density (BMD) of femurs from 15-week-old indicated mice, as measured by DEXA. Data represent mean BMD (mg/cm<sup>2</sup>) of each time point  $\pm$  SD ( $n = 6$ ,  $*p < 0.05$ ).

particular organ or tissue controls aging. Here, we show that chondrocyte-specific *Enpp1* deletion results in a significantly shortened life span. Thus, cartilage tissue plays a role in controlling systemic aging and that *Enpp1* activity functions in this process.

Among factors that control aging, genetic factors are known to cause premature aging in a variety of disorders (29, 32), such as Werner syndrome or Hutchinson-Gilford-Progeria syndrome (33, 34). However, phenotypes associated with these diseases are apparent very early after birth in humans and represent pathological rather than general aging (35). Here, we report that *Col2a1* Cre/*Enpp1* cKO mice fed a HPD as adults show various phenotypes characteristic of normal aging, such as ectopic calcification of kidney and osteoporosis. In mice, the *Col2a1* promoter is highly active in early development and then becomes less so in adult animals (26, 27). Since *Enpp1* is expressed in growth plate chondrocytes in developing stages (Fig. 1D), we chose to use *Col2a1* Cre mice to delete the *Enpp1* gene in chondrocytes. Meanwhile, Aggrecan Cre mice have been used by others to examine postnatal phenotypes such as osteoarthritis (36). Nonetheless, since *Col2a1* Cre/*Enpp1* cKO mice exhibit significantly shortened life span compared with controls, *Enpp1* expression in chondrocytes likely plays a role in regulating systemic aging throughout life.

Proper regulation of phosphate metabolism is reportedly crucial to suppress ectopic calcification, such as that occurring in dialysis patients when renal function is impaired (1, 37). In this study, we found that cartilage tissue regulates systemic ectopic calcification, a finding that was unanticipated. Articular cartilage maintains homeostasis by not calcifying, which also contributes to prevention of global calcification. It is also well known that PPI, which is produced prior to phosphorus synthesis, is the most important factor in preventing calcification (10). *Enpp1* activity regulates PPI levels, and *Enpp1*-deficient *ttw* mice exhibit reduced blood PPI levels (Fig. 2E). Here, we show that *Col2a1* Cre/*Enpp1* cKO mice also exhibit significantly reduced blood PPI phosphate levels, and thus cartilage tissue is a likely regulator of systemic PPI levels, ectopic calcification, and aging through *Enpp1* activity. However, phenotypes seen in *Col2a1* Cre/*Enpp1* cKO mice were not completely identical to those seen in CAG Cre/*Enpp1* cKO mice, and serum PPI levels were significantly lower in CAG Cre/*Enpp1* cKO compared to *Col2a1* Cre/*Enpp1* cKO mice (Figs. 2D and 3E). These observations suggest that *Enpp1* expressed below the detection limit of bioluminescence or fluorescence immunostaining in noncartilaginous tissues has activity similar to *Enpp1* expressed in cartilaginous tissues.

Osteoarthritis due to cartilage degeneration is a typical disease of aging, but conversely, degeneration may be caused by cartilage tissue dysfunction. In fact, ectopic ossification such as osteophytes is observed in osteoarthritis, and osteoarthritis reportedly correlates with osteoporosis, another age-related disease (38, 39). We demonstrate that *Col2a1* Cre/*Enpp1* cKO mice fed a HPD exhibit significantly reduced bone mass. These findings suggest that ectopic calcification decreases proper calcium deposition in bones, leading to osteoporosis due to reduced bone mineral density. Indeed,

calcification of the abdominal aorta is known to correlate with osteoporosis development (40, 41). Maintaining homeostasis of cartilage tissue may be required to control systemic aging, including osteoporosis.

Currently, calorie restriction is the only known evidence-based method across species that slows the aging process (42, 43). By contrast, high caloric intake leads to several diseases that shorten life span, such as atherosclerosis (42, 43). We show that conditions observed with high caloric intake, including ectopic calcification in kidney and osteoporosis, are also seen in *Col2a1* Cre/*Enpp1* cKO mice fed an HPD. Regulation of phosphorus metabolism by *Enpp1* may have similar significance to calorie restriction in aging regulation.

Low blood vitamin D levels are a well-known risk factor for osteoporosis development and fragility fractures in the elderly (41, 44). However, this study showed that vitamin D is a risk factor for ectopic calcification and osteoporosis when *Enpp1* function is disrupted. Control of phosphorus metabolism and vitamin D levels may be important for future control of aging and prevention of osteoporosis fragility fractures. Taken together, our study indicates that cartilage represents as a control center of systemic aging *via* *Enpp1*.

### Experimental procedures

#### Mice and diets

The *ttw* mice, a spontaneous mutant harboring a mutation in the *Enpp1* gene (16, 17), were maintained as described (20). The *Enpp1*-EGFP-luciferase reporter mice (Accession No. CDB0010E: <https://large.riken.jp/distribution/mutant-list.html>) were established by knocking in a chimeric sequence of EGFP and firefly luciferase at the start codon of exon 1 of mouse *Enpp1* gene using CRISPR/Cas9-mediated genome editing in zygotes as previously described (45). *Enpp1* flox/flox mice were generated by creating loxP sequences at both ends of *Enpp1* exon 18, since *ttw* mice carry a nonsense mutation in that exon (17). CAG Cre mice were prepared as described (46), as were *Col2a1* Cre mice (47). WT mice were obtained from CLEA Japan, Inc (Meguro). Primers for genotyping PCR were as follows.

*Enpp1*-EGFP-luciferase reporter-forward:5'-CGACCTAC-CAGCGACAGC-3'

*Enpp1*-EGFP-luciferase reporter-reverse:5'-TCATCGA-CAAGTACGACCTAAGCA-3'

*Enpp1*-flox/flox-forward:5'-CACATCTCTCTGTGTGTGTGCA-3'

*Enpp1*-flox/flox-reverse:5'-GCAG-TAAGTTGGGGTTGGGCC-3'

Mice were fed either a normal phosphate diet (1% phosphate, ND), a HPD (1.5–2% phosphate), or a HPLD (1.5% phosphate) starting at 8 weeks of age for at least 2 weeks or for indicated periods. The HPLD contains 0 units/100 g Vitamin D units. The other diets contain Vitamin D 240 units/100 g. Animal experiments were approved by the Institutional Animal Ethics Committees of Kumamoto University (approval A2020-127, A 2022-024) and the Institutional Animal Care

## Cartilage tissues regulate systemic aging via *Enpp1* in mice

and Use Committee of RIKEN Kobe Branch (Approval number: A2001-03).

### Bioluminescence imaging

The IVIS spectrum cooled charge-coupled device optical macroscopic imaging system (Caliper Life Sciences) was used for *in vitro* and *in vivo* bioluminescence imaging, as reported by others (48). *In vivo* imaging was performed 15 min after i.p. injection of D-luciferin (0.15 mg/g body weight) (Cayman Chemical Company) with the field-of-view set at 13.2 cm, since photon count was most stable during this period. Intensity peaked between 15 and 30 min after i.p. D-luciferin injection. Mice were euthanized 20 min after injection. Each tissue was then isolated, followed by *ex vivo* bioluminescence imaging. Integration time was fixed at 15 s for each image.

For *in vitro* imaging, chondrocytes were pellet cultured and treated with D-luciferin (0.5 mM), and images were taken 15 min later. Integration time was fixed at 60 s for each image.

### Quantitative PCR analysis

Total RNAs were isolated from indicated tissues using TRIzol reagent (Invitrogen Corp). RNA samples were quantified based on A260/A280 ratios using a Thermo Scientific NanoDrop One spectrophotometer (Thermo Fisher Scientific). Samples with A260/A280 ratios >1.8 were considered pure and subjected to cDNA synthesis. A Prime Script RT reagent Kit (Takara Bio Inc) was used for reverse transcription of mRNA. cDNA was synthesized using a Thermal Cycler Dice (Takara Bio Inc) according to the manufacturer's instructions.

Quantitative real-time PCR was performed using TB Green Premix ExTaq II reagent (Takara Bio Inc) and a Thermal Cycler Dice (Takara Bio Inc) according to the manufacturer's instructions.  $\beta$ -actin (*Actb*) expression served as an internal control. Primers for real-time PCR were as follows.

*mEnpp1*-forward: 5'-AAGCATGGTGCTGAAGTTGACTC-3'  
*mEnpp1*-reverse: 5'-TGGGATGACTTGGGTTGTAAATG-3'  
*Klotho*-forward: 5'-GACAATGGCTTTCCTCCTTACCT-3'  
*Klotho*-reverse: 5'-TGCACATCCCACAGATAGACATTC-3'  
*Cyp27b1*-forward: 5'-ACTCAGCTTCCTGGCTGAACTCTT-3'  
*Cyp27b1*-reverse: 5'-GTAAACTGTGCGAAGTGTCCCAA-3'  
 *$\beta$ -actin* (*Actb*)-forward: 5' – AAGTGTGACGTTGACATCCG-3'  
 *$\beta$ -actin* (*Actb*)-reverse: 5' – GATCCACATCTGCTGGAAGG -3'

### micro CT

Vertebral bones and surrounding tissues, including intervertebral discs, the posterior longitudinal ligament, and Achilles tendon, were scanned by a microcomputed tomography (Sky-Scan1176, Bruker). Two-dimensional regions of interest were created at the level of the cervical spine and Achilles tendon.

### Histopathological analysis

Tissue samples were fixed 2 h in 4% PFA/PBS at 4 °C, treated with 20% sucrose in PBS, and frozen in SCEM-L1 compound (Section-lab). Samples were then cryosectioned to a thickness of 4  $\mu$ m and stained with hematoxylin and eosin and von Kossa or Alizarin Red. Sections were observed under a microscope (BZ-X700 microscope, Keyence), and digital images were captured.

### Immunohistochemistry

Antigen retrieval was performed using 0.05% proteinase K (Kanto chemical co, INC) in PBS for 15 min at room temperature. Sections were then incubated in 3% BSA in PBS for blocking and stained with primary antibodies at 4 °C. Subsequently sections were washed and incubated with Alexa488-conjugated goat anti rabbit Ig's antibody (diluted 1:400), Alexa488-conjugated donkey anti goat Ig's antibody(diluted 1:200) or Alexa594-conjugated Donkey anti rabbit Ig's antibody (diluted 1:200) (Life Technologies Corporation) for 120 min at 4 °C. Slides were mounted and counterstained with Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories) and were imaged under a fluorescence microscope (BZ-X700). Primary antibodies used were anti-GFP (diluted 1:1000; Code No. 598, MBL), Goat anti-EGFP (diluted 1:250; ab6673, Abcam), rabbit anti-Type 2 collagen (diluted 1:200; ab34712, Abcam), and rabbit anti-CDKN2A/p16INK4a (diluted 1:200; SAB5700620, Sigma-Aldrich).

### Chondrocyte culture

Chondrocytes from rib cartilage were prepared from 1-week-old C57/B6 mice and from *Enpp1*-luciferase-EGFP KI mice, as previously reported (49).

### Measurement of plasma PPI

For PPI analysis, plasma was collected from mice, and samples were filtered through a 30 kDa membrane (PALL) by centrifugation to remove platelets. Plasma was frozen at -80 °C within 1 h of blood collection for single use. Measurement of plasma PPI was performed using ATP sulfurylase with slight modifications of previous protocols (50–52).

### Flow cytometry

Bone marrow was extracted from mouse femur and tibia. Using a 70  $\mu$ m cell strainer (pluriSelect), suspensions were filtered to remove debris and then layered on lympholyte-M medium (Cedarlane Laboratories Ltd) for purification. Cells were then stained 20 min with an appropriate monoclonal antibody. Antibodies used were anti-mouse CD31-PE (102508, BioLegend), anti-mouse CD45-FITC(11-0451-82, Thermo Fisher Scientific), and anti-mouse PDGFR $\alpha$ -APC (17-1401-81, Thermo Fisher Scientific). Flow cytometry was performed with FACSVerse (BD Biosciences), and the data were analyzed using Flowjo software (BD Biosciences). Gates for MSCs were defined as positivity for PDGFR- $\alpha$  and negativity for CD31, CD45, according to the fluorescence intensity of the isotype control.



### Analysis of skeletal morphology

Bone mineral density of whole femurs was measured using Dual-energy X-ray absorptiometry.

### Statistical analyses

All results are reported as the mean  $\pm$  standard error (SD). We used the Mann–Whitney U test and Kruskal–Wallis test to calculate *p* values. A *p* value  $< 0.05$  was considered statistically significant (\**p*  $< 0.05$ ; \*\**p*  $< 0.01$ ; \*\*\**p*  $< 0.001$ ).

### Data availability

A summary of all original data are presented in the manuscript, including all individual data points collected. Unprocessed data are available on request from the corresponding author: Takeshi Miyamoto ([miyamoto.takeshi@kuh.kumamoto-u.ac.jp](mailto:miyamoto.takeshi@kuh.kumamoto-u.ac.jp)).

**Supporting information**—This article contains supporting information.

**Acknowledgments**—T. Miyamoto was supported by a grant-in-aid for Scientific Research in Japan.

**Author contributions**—T. M., K. S., T. T., K. M., Y. S., T. K., Takuya Tokunaga, T. S., S. H., Tetsuro Masuda, Y. U., M. Y., Kozo Matsushita, R. Y., J. K., N. Y., S. T., and T. N. conceptualization; T. M., T. A., and M. T. validation; T. M., K. S., K. B., and K. I. resources; T. M. and T. A. writing—original draft; T. M. project administration; T. M. and K. S. funding acquisition; T. A., K. I., K. B., H. K., and N. I. methodology; T. A., J. K., N. Y., H. K., and N. I. formal analysis; T. A. investigation; T. A. and M. T. data curation; T. A. visualization; T. M., T. N., K. S., T. T., K. M., Y. S., T. K., Takuya Tokunaga, T. S., S. H., Tetsuro Masuda, Y. U., M. Y., Kozo Matsushita, R. Y., and T. N. supervision; K. S. project administration.

**Conflict of interest**—The authors declare no conflict of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: cKO, conditional knockout; *Enpp1*, ectonucleotide pyrophosphatase/phosphodiesterase 1; HPD, high-phosphate diet; HPLD, high-phosphate/low vitamin D diet; KI, knock-in; ND, normal diet; PPI, pyrophosphate.

### References

1. Stubbs, J. R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., *et al.* (2007) Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. *J. Am. Soc. Nephrol.* **18**, 2116–2124
2. Stenvinkel, P., and Larsson, T. E. (2013) Chronic kidney disease: a clinical model of premature aging. *Am. J. Kidney Dis.* **62**, 339–351
3. McClelland, R., Christensen, K., Mohammed, S., McGuinness, D., Cooney, J., Bakshi, A., *et al.* (2016) Accelerated ageing and renal dysfunction links lower socioeconomic status and dietary phosphate intake. *Aging (Albany NY)* **8**, 1135–1149
4. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., *et al.* (2004) Targeted ablation of *Fgf23* demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. *J. Clin. Invest.* **113**, 561–568

5. Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., *et al.* (2004) Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in *Phex*-deficient mice. *Matrix Biol.* **23**, 421–432
6. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., *et al.* (1997) Mutation of the mouse *klotho* gene leads to a syndrome resembling ageing. *Nature* **390**, 45–51
7. Araya, K., Fukumoto, S., Backenroth, R., Takeuchi, Y., Nakayama, K., Ito, N., *et al.* (2005) A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. *J. Clin. Endocrinol. Metab.* **90**, 5523–5527
8. Ichikawa, S., Imel, E. A., Kreiter, M. L., Yu, X., Mackenzie, D. S., Sorenson, A. H., *et al.* (2007) A homozygous missense mutation in human *KLOTHO* causes severe tumoral calcinosis. *J. Clin. Invest.* **117**, 2684–2691
9. Johnson, K. A., Hesse, L., Vaingankar, S., Wennberg, C., Mauro, S., Narisawa, S., *et al.* (2000) Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **279**, R1365–1377
10. Rutsch, F., Ruf, N., Vaingankar, S., Toliat, M. R., Suk, A., Höhne, W., *et al.* (2003) Mutations in *ENPP1* are associated with ‘idiopathic’ infantile arterial calcification. *Nat. Genet.* **34**, 379–381
11. Rutsch, F., Vaingankar, S., Johnson, K., Goldfine, I., Maddux, B., Schauerte, P., *et al.* (2001) PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. *Am. J. Pathol.* **158**, 543–554
12. Levy-Litan, V., Hershkovitz, E., Avizov, L., Leventhal, N., Bercovich, D., Chalifa-Caspi, V., *et al.* (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the *ENPP1* gene. *Am. J. Hum. Genet.* **86**, 273–278
13. Lorenz-Depiereux, B., Schnabel, D., Tiosano, D., Häusler, G., and Strom, T. M. (2010) Loss-of-function *ENPP1* mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. *Am. J. Hum. Genet.* **86**, 267–272
14. Nakamura, I., Ikegawa, S., Okawa, A., Okuda, S., Koshizuka, Y., Kawaguchi, H., *et al.* (1999) Association of the human *NPPS* gene with ossification of the posterior longitudinal ligament of the spine (OPLL). *Hum. Genet.* **104**, 492–497
15. Koshizuka, Y., Kawaguchi, H., Ogata, N., Ikeda, T., Mabuchi, A., Seichi, A., *et al.* (2002) Nucleotide pyrophosphatase gene polymorphism associated with ossification of the posterior longitudinal ligament of the spine. *J. Bone Miner. Res.* **17**, 138–144
16. Okawa, A., Ikegawa, S., Nakamura, I., Goto, S., Moriya, H., and Nakamura, Y. (1998) Mapping of a gene responsible for *twy* (tip-toe walking Yoshimura), a mouse model of ossification of the posterior longitudinal ligament of the spine (OPLL). *Mamm. Genome* **9**, 155–156
17. Okawa, A., Nakamura, I., Goto, S., Moriya, H., Nakamura, Y., and Ikegawa, S. (1998) Mutation in *Npps* in a mouse model of ossification of the posterior longitudinal ligament of the spine. *Nat. Genet.* **19**, 271–273
18. Li, Q., Guo, H., Chou, D. W., Berndt, A., Sundberg, J. P., and Uitto, J. (2013) Mutant *Enpp1asj* mice as a model for generalized arterial calcification of infancy. *Dis. Model Mech.* **6**, 1227–1235
19. Koshizuka, Y., Ikegawa, S., Sano, M., Nakamura, K., and Nakamura, Y. (2001) Isolation of novel mouse genes associated with ectopic ossification by differential display method using *ttw*, a mouse model for ectopic ossification. *Cytogenet. Cell Genet.* **94**, 163–168
20. Watanabe, R., Fujita, N., Sato, Y., Kobayashi, T., Morita, M., Oike, T., *et al.* (2017) *Enpp1* is an anti-aging factor that regulates *Klotho* under phosphate overload conditions. *Sci. Rep.* **7**, 7786
21. Harahap, A. R., and Goding, J. W. (1988) Distribution of the murine plasma cell antigen PC-1 in non-lymphoid tissues. *J. Immunol.* **141**, 2317–2320
22. Liang, J., Fu, M., Ciociola, E., Chandalia, M., and Abate, N. (2007) Role of *ENPP1* on adipocyte maturation. *PLoS One* **2**, e882
23. Nitschke, Y., Weissen-Plenz, G., Terkeltaub, R., and Rutsch, F. (2011) *Npp1* promotes atherosclerosis in ApoE knockout mice. *J. Cell. Mol. Med.* **15**, 2273–2283
24. Ito, N., Wijenayaka, A. R., Prideaux, M., Kogawa, M., Ormsby, R. T., Evdokiou, A., *et al.* (2015) Regulation of FGF23 expression in IDG-SW3

## Cartilage tissues regulate systemic aging via *Enpp1* in mice

- osteocytes and human bone by pro-inflammatory stimuli. *Mol. Cell. Endocrinol.* **399**, 208–218
25. Hosoda, Y., Yoshimura, Y., and Higaki, S. (1981) A new breed of mouse showing multiple osteochondral lesions—twy mouse. *Ryumachi* **21 Suppl**, 157–164
  26. Mayne, R. (1990) Collagen types and chondrogenesis. *Ann. N. Y. Acad. Sci.* **599**, 39–44
  27. Cheah, K. S., Lau, E. T., Au, P. K., and Tam, P. P. (1991) Expression of the mouse alpha 1(II) collagen gene is not restricted to cartilage during development. *Development* **111**, 945–953
  28. LaPak, K. M., and Burd, C. E. (2014) The molecular balancing act of p16(INK4a) in cancer and aging. *Mol. Cancer Res.* **12**, 167–183
  29. Lee, S. S., Lee, R. Y., Fraser, A. G., Kamath, R. S., Ahringer, J., and Ruvkun, G. (2003) A systematic RNAi screen identifies a critical role for mitochondria in *C. elegans* longevity. *Nat. Genet.* **33**, 40–48
  30. Kapahi, P., Chen, D., Rogers, A. N., Katewa, S. D., Li, P. W., Thomas, E. L., et al. (2010) With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. *Cell Metab.* **11**, 453–465
  31. Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., and Verdin, E. (2019) From discoveries in ageing research to therapeutics for healthy ageing. *Nature* **571**, 183–192
  32. Bartke, A. (2008) Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings. *Aging Cell* **7**, 285–290
  33. Oshima, J., Sidorova, J. M., and Monnat, R. J., Jr. (2017) Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. *Ageing Res. Rev.* **33**, 105–114
  34. Gonzalo, S., Kreienkamp, R., and Askjaer, P. (2017) Hutchinson-gilford progeria syndrome: a premature aging disease caused by LMNA gene mutations. *Ageing Res. Rev.* **33**, 18–29
  35. Ullrich, N. J., and Gordon, L. B. (2015) Hutchinson-Gilford progeria syndrome. *Handb. Clin. Neurol.* **132**, 249–264
  36. Henry, S. P., Jang, C. W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugge, B. (2009) Generation of aggrecan-CreERT2 knockin mice for inducible Cre activity in adult cartilage. *Genesis* **47**, 805–814
  37. Gonzalo, S., and Villa-Bellosta, R. (2019) The role of sodium phosphate cotransporters in ectopic calcification. *Endokrynol. Pol.* **70**, 496–503
  38. Nevitt, M. C., Lane, N. E., Scott, J. C., Hochberg, M. C., Pressman, A. R., Genant, H. K., et al. (1995) Radiographic osteoarthritis of the hip and bone mineral density. The study of osteoporotic fractures research group. *Arthritis Rheum.* **38**, 907–916
  39. Zhang, Y., Hannan, M. T., Chaisson, C. E., McAlindon, T. E., Evans, S. R., Aliabadi, P., et al. (2000) Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the framingham study. *J. Rheumatol.* **27**, 1032–1037
  40. Szulc, P., Blackwell, T., Schousboe, J. T., Bauer, D. C., Cawthon, P., Lane, N. E., et al. (2014) High hip fracture risk in men with severe aortic calcification: MrOS study. *J. Bone Miner. Res.* **29**, 968–975
  41. El Maghraoui, A., Hamza, T., Sadni, S., El Maataoui, A., Majjad, A., Rezqi, A., et al. (2018) Vitamin D status and abdominal aortic calcification in postmenopausal women. *J. Bone Miner. Metab.* **36**, 229–237
  42. Omodei, D., and Fontana, L. (2011) Calorie restriction and prevention of age-associated chronic disease. *FEBS Lett.* **585**, 1537–1542
  43. Mattison, J. A., Colman, R. J., Beasley, T. M., Allison, D. B., Kemnitz, J. W., Roth, G. S., et al. (2017) Caloric restriction improves health and survival of rhesus monkeys. *Nat. Commun.* **8**, 14063
  44. Tamaki, J., Iki, M., Sato, Y., Kajita, E., Nishino, H., Akiba, T., et al. (2017) Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. *Osteoporos. Int.* **28**, 1903–1913
  45. Abe, T., Inoue, K. I., Furuta, Y., and Kiyonari, H. (2020) Pronuclear microinjection during S-phase increases the efficiency of CRISPR-Cas9-Assisted knockin of large DNA donors in mouse zygotes. *Cell Rep.* **31**, 107653
  46. Sakai, K., and Miyazaki, J. (1997) A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. *Biochem. Biophys. Res. Commun.* **237**, 318–324
  47. Ovchinnikov, D. A., Deng, J. M., Ogunrinu, G., and Behringer, R. R. (2000) Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. *Genesis* **26**, 145–146
  48. Nishimura, S., Yasuda, A., Iwai, H., Takano, M., Kobayashi, Y., Nori, S., et al. (2013) Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury. *Mol. Brain* **6**, 3
  49. Camper, L., Holmval, K., Wängnerud, C., Aszódi, A., and Lundgren-Akerlund, E. (2001) Distribution of the collagen-binding integrin alpha10beta1 during mouse development. *Cell Tissue Res.* **306**, 107–116
  50. Jansen, R. S., Küçükosmanoglu, A., de Haas, M., Sapthu, S., Otero, J. A., Hegman, I. E., et al. (2013) ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 20206–20211
  51. Jansen, R. S., Duijst, S., Mahakena, S., Sommer, D., Szeri, F., Váradi, A., et al. (2014) ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation—brief report. *Arterioscler. Thromb. Vasc. Biol.* **34**, 1985–1989
  52. Kato, H., Ansh, A. J., Lester, E. R., Kinoshita, Y., Hidaka, N., Hoshino, Y., et al. (2022) Identification of ENPP1 Haploinsufficiency in patients with diffuse idiopathic skeletal hyperostosis and early-Onset osteoporosis. *J. Bone Miner. Res.* **37**, 1125–1135